Press Releases Cybin Inc.

Equities

CYBN

CA23256X1006

Market Closed - Nyse Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
0.35 ^USD	-.--%		-1.41%	-14.63%

Apr. 17	Numinus Wellness Brief: Says Cedar Clinical Research Selected as clinical research site for Cybin's Phase 3 Study of CYB003	MT
Apr. 16	Cybin Secures US Patent for CYB003 Program in Major Depressive Disorder Treatment	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cybin to Participate at the 27th Annual Milken Institute Global Conference	Apr. 25	BU
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry	Apr. 18	BU
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder	Apr. 16	BU
Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference	Apr. 10	BU
Cybin : MATERIAL CHANGE REPORT - Form 6-K	Mar. 22	PU
Cybin : AGENCY AGREEMENT - Form 6-K	Mar. 21	PU
Cybin to Present at Public Ventures Discovery Day on March 19th in Dallas	Mar. 18	BU
Cybin Initiates Phase 2 Proof-of-Concept Study of CYB004 in Generalized Anxiety Disorder	Mar. 15	BU
Discovering Promising Tech Stocks: QBTS, GEVI, CYBN, RSCI, CLRO	Mar. 15	AQ
Cybin Announces Positive End-of-Phase 2 Meeting with FDA for CYB003 in Major Depressive Disorder and Phase 3 Program Design	Mar. 14	BU
Cybin Inc. - Announces Oversubscribed Private Placement of U.S. $150 Million	Mar. 14	AQ
Cybin Receives FDA Breakthrough Therapy Designation for its Novel Psychedelic Molecule CYB003 and Announces Positive Four-Month Durability Data in Major Depressive Disorder	Mar. 13	BU
Cybin to Host Conference Call and Webcast to Provide Program Update for CYB003	Mar. 12	BU
Cybin to Present at the TD Cowen 44th Annual Health Care Conference	Feb. 27	BU
Cybin Reports Third Quarter Financial Results and Recent Business Highlights	Feb. 14	BU
Cybin Announces Grant of Two Additional Patents in Japan in Support of its DMT Program	Feb. 07	BU
Cybin Announces FDA Clearance to Initiate a Phase 2a Study of CYB004 in Generalized Anxiety Disorder	Jan. 23	BU
Cybin Announces Positive Topline Data from Phase 1 Studies of Proprietary Deuterated DMT Molecules CYB004 and SPL028	Jan. 08	BU
Cybin Highlights Recent Topline Results and Outlines Key Upcoming Milestones Across its Clinical Development Programs	Jan. 04	BU
Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program	Dec. 06	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Cybin Inc.

Equities

CYBN

CA23256X1006

Press Releases

Filters